Please try another search
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Kathryn Haviland | 46 | 2018 | Independent Chair of the Board |
Leslie Leinwand | - | - | Member of Scientific Advisory Board |
James J. Collins | 57 | 2017 | Independent Director |
Baziel van Engelen | - | - | Member of FSHD Clinical Advisory Board |
Sonja L. Banks | 54 | 2021 | Independent Director |
H. Lee Sweeney | - | - | Member of Scientific Advisory Board |
Silvere van der Maarel | - | - | Member of FSHD Clinical Advisory Board |
Rabi Tawil | - | - | Member of FSHD Clinical Advisory Board |
Donald E. Ingber | - | 2021 | Member of Scientific Advisory Board |
Jeffrey Statland | - | - | Member of FSHD Clinical Advisory Board |
Patrick Trojer | 50 | 2022 | Member of Scientific Advisory Board |
Robert J. Gould | 68 | 2016 | Director |
James Arthur Geraghty | 68 | 2016 | Independent Director |
Alan Ezekowitz | 69 | 2016 | Independent Director |
Katina Dorton | 65 | 2020 | Independent Director |
Alexander C. Sapir | 57 | 2023 | CEO, President & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review